Understanding the cross-talk between ovarian tumors and immune cells: Mechanisms for effective immunotherapies

International Reviews of Immunology

Volumn 30, Issue 2-3, 2011, Pages 71-86

  Chiriva Internati, Maurizio ^a,b   Mirandola, Leonardo ^a,b   Kast, W Martin ^c,d   Jenkins, Marjorie R ^a,b   Cobos, Everardo ^a,b   Cannon, Martin J ^e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

adoptive immunotherapies; dendritic cells; Ovarian cancer; recombinant adeno associated virus; T cells; T reg

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CANCER TESTIS ANTIGEN; DENDRITIC CELL VACCINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MITOGEN ACTIVATED PROTEIN KINASE P38; OLAPARIB; PARVOVIRUS VECTOR; PROVENGE; THALIDOMIDE; TOZASERTIB; TUMOR VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DENDRITIC CELL; ENZYME INHIBITION; GENE DELIVERY SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; NONHUMAN; OVARY CANCER; OVARY TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79955790524     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.561507     Document Type: Article

References (107)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907.
3. Cheng W, Liu J, Yoshida H, et al. Lineage infdelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005;11:531-537. (Pubitemid 40685976)
4. Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol Oncol 2011;120:152-157.
5. Russo A, Calo V, Bruno L, et al. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009;69:28-44.
6. Coukos G, Rubin SC. Prophylactic oophorectomy. Best Pract Res Clin Obstet Gynaecol 2002;16:597-609. (Pubitemid 41123409)
7. Salani R, Backes FJ, Copeland LJ. Overview of epithelial ovarian cancer and updates in management strategies. Expert Rev Obstet & Gynecol 2009;4:383-399.
8. Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ter 2009;9:1727-1735.
9. Zhou G, Drake CT, Levitsky HI. Amplifcation of tumor-specifc regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628-636. (Pubitemid 43076387)
10. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887. (Pubitemid 13014028)
11. Buller RE, Berman ML, Bloss JD, et al. Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment fndings and survival. Gynecol Oncol 1992;47:87-92.
12. Cooper BC, Sood AK, Davis CS, et al. Preoperative CA 125 levels: An independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002;100:59-64. (Pubitemid 34722843)
13. Alagoz T, Buller RE, Berman M, et al. What is a normal CA125 level? Gynecol Oncol 1994;53:93-97. (Pubitemid 24136908)
14. Vermeij R,Daemen T, de Bock GH, et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010;891505:15.
15. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted gly-coprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-2169. (Pubitemid 40490123)
16. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration diferentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-1319.
17. Schorge JO,Modesitt SC,ColemanRL, et al. SGOWhite Paper on ovarian cancer:Etiology,screening and surveillance. Gynecol Oncol 2010; 119:7-17.
18. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15. (Pubitemid 39286271)
19. Lambeck AJ, Crijns AP, Lefers N, et al. Serum cytokine profling as a diagnostic and prognostic tool in ovarian cancer: A potential role for interleukin 7. Clin Cancer Res 2007;13:2385-2391. (Pubitemid 46698588)
20. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918. (Pubitemid 27113936)
21. Nelson PT, Zhang PJ, Spagnoli GC, et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007;7:1.
22. Valmori D, Qian F, Ayyoub M, et al. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identifcation of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006;12:398-404. (Pubitemid 43166127)
23. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b pep-tide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk frst remission. Clin Cancer Res 2008;14:2740-2748.
24. Li S, Meng L, Zhu C, et al. The universal overexpression of a cancer testis antigen HIWI is associated with cancer angiogenesis. Oncol Rep 2010;23:1063-1068.
25. Chen YT, Hsu M, Lee P, et al. Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer 2009;124:2893-2898.
26. Piura B, Piura E. Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol 2009;581939:17.
27. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infltrating NY-ESO-1-specifc CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 2010;107:7875-7880.
28. Chiriva-Internati M, Wang Z, Salati E, et al. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002;94:2447-2453. (Pubitemid 34457127)
29. Straughn JM Jr, Shaw DR, Guerrero A, et al. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004;108:805-811. (Pubitemid 38112606)
30. Chiriva-Internati M, Yu Y, Mirandola L, et al. Cancer testis antigen vaccination afords long-term protection in a murine model of ovarian cancer. PLoS One 2010 May 12;5(5):e10471.
31. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008;86:140-146. (Pubitemid 351213717)
32. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-1355.
33. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efcacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007;369:1693-1702. (Pubitemid 46783792)
34. Tun MJ, DeLancey JO, Center MM, et al. The global burden of cancer: Priorities for prevention. Carcinogenesis 2010;31:100-110.
35. Van der Bruggen P,Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647. (Pubitemid 21917508)
36. Koos D, Josephs SF, Alexandrescu DT, et al. Tumor vaccines in 2010: Need for integration. Cell Immunol 2010;263:138-147.
37. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252. (Pubitemid 28155090)
38. Kantof PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
39. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol. 2000;68:793-806.
40. Sallusto F, Lanzavecchia A. Efcient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
41. Santin AD, Hermonat PL, Ravaggi A, et al. Expression of surface antigens during the diferenti-ation of human dendritic cells vs macrophages from blood monocytes in vitro. Immunobiology 1999;200:187-204. (Pubitemid 29292211)
42. Santin AD, Hermonat PL, Ravaggi A, et al. In vitro induction of tumor-specifc human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-609.
43. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33-45. (Pubitemid 32587693)
44. Chiriva-Internati M, Liu Y, Salati E, et al. Efcient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene trans-duction into dendritic cells. Eur J Immunol 2002;32:30-38. (Pubitemid 34092819)
45. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010;2:37-56.
46. Yu Y, Pilgrim P, Zhou W, et al. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008;21:435-442.
47. Palladino G, Scherle PA, Gerhard W. Activity of CD4+T-cell clones of type 1 and type 2 in generation of infuenza virus-specifc cytotoxic responses in vitro. J Virol 1991;65:6071-6076.
48. Nonacs R, Humborg C, Tam JP, Steinman RM. Mechanisms of mouse spleen dendritic cell function in the generation of infuenza-specifc, cytolytic T lymphocytes. J Exp Med 1992;176:519-529.
49. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: Properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984;51:611-619. (Pubitemid 14063135)
50. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998;72:5919-5926. (Pubitemid 28283380)
51. Fisher-Adams G, Wong KK Jr, Podsakof G, et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996;88:492-504. (Pubitemid 26240381)
52. Chiriva-Internati M, Liu Y, Weidanz JA, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003;102:3100-3107. (Pubitemid 37314744)
53. Bohenzky RA, LeFebvre RB, Berns KI. Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat. Virology 1988;166:316-327.
54. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defned structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568-8577. (Pubitemid 28471794)
55. Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ter 1998;5:40-49. (Pubitemid 28045068)
56. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ter 1997;8:659-669. (Pubitemid 27202053)
57. Gilbert C, Maxfeld DG, Goodman SM, Feschotte C. Parallel germline infltration of a lentivirus in two Malagasy lemurs. PLoS Genet 2009;5:20.
58. Sabatino DE, Mingozzi F, Hui DJ, et al. Identifcation of mouse AAV capsid-specifc CD8+ T cell epitopes. Mol Ter 2005;12:1023-1033. (Pubitemid 41723036)
59. Curielj TJ, Coukos G, Zou L, et al. Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735)
60. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543. (Pubitemid 43011261)
61. Giuntoli RL 2nd, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Res 2009;29:2875-2884.
62. Gray A, de la Luz Garcia-Hernandez M, Van West M, et al. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogen-esis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009;30:G52-G59.
63. Warrino DE, Olson WC, Scarrow MI, et al. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specifc T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol 2005;66:762-772. (Pubitemid 41169766)
64. Kriegel MA, Li MO, Sanjabi S, et al. Transforming growth factor-beta: Recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006;8:138-144. (Pubitemid 44623982)
65. Rosano L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasive-ness of ovarian carcinoma cells. Cancer Res 2001;61:8340-8346. (Pubitemid 33091630)
66. Rodriguez GC, Haisley C, Hurteau J, et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001;80:245-253. (Pubitemid 32158466)
67. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifes a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-881.
68. Kryczek I, Wei S, Vatan L, et al. Cutting edge: Opposite efects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007;179:1423-1426.
69. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-5026. (Pubitemid 40827308)
70. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003;527:183-190. (Pubitemid 38197643)
71. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-1154. (Pubitemid 46718399)
72. Copier J, Dalgleish AG, Britten CM, et al. Improving the efcacy of cancer immunotherapy. Eur J Cancer 2009;45:1424-1431.
73. Reali E, Canter D, Zeytin H, et al. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with diferent vaccine platforms. Vaccine 2005;23:2909-2921. (Pubitemid 40386493)
74. Limpens J, Scheper RJ. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site. Clin Exp Immunol 1991;84:383-388.
75. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine. Biologics 2007;1:173-181.
76. Karbach J, Gnjatic S, Bender A, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. Int J Cancer 2010;126:909-918.
77. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
78. Hermans IF, Silk JD, Gileadi U, et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 2007;178:2721-2729. (Pubitemid 46333148)
79. Galli G, Pittoni P, Tonti E, et al. Invariant NKT cells sustain specifc B cell responses and memory. Proc Natl Acad Sci USA 2007;104:3984-3989. (Pubitemid 47181565)
80. Choi YS, Hoory T, Monie A, et al. alpha-Galactosylceramide enhances the protective and therapeutic efects of tumor cell based vaccines for ovarian tumors. Vaccine 2008;26:5855-5863.
81. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active spe-cifc immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12. (Pubitemid 28430525)
82. Berd D, Sato T, Maguire HC Jr, et al. Immunopharmacologic analysis of an autologous, hapten-modifed human melanoma vaccine. J Clin Oncol 2004;22:403-415. (Pubitemid 41079768)
83. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989;49:1649-1654. (Pubitemid 19108381)
84. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633. (Pubitemid 43121851)
85. Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: Is it an immune suppressor? Cancer J 2010;16:354-359.
86. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-5171. (Pubitemid 350237599)
87. Downs LS Jr, Judson PL, Argenta PA, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112:331-339.
88. Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase III trial of tamoxifen versus thalidomide in womenwith biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to frst-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 2010;119:444-450.
89. Brabec V, Kasparkova J. Modifcations of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Update 2005;8:131-146. (Pubitemid 41267064)
90. Lin YG, Immaneni A, Merritt WM, et al. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008;14:5437-5446.
91. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an efective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-1679. (Pubitemid 46383393)
92. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85-94.
93. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-4368.
94. Barre B, Vigneron A, Perkins N, et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11. (Pubitemid 46027724)
95. Greenhill CJ, Rose-John S, Lissilaa R, et al. IL-6 trans-signaling modulates TLR4-dependent infam-matory responses via STAT3. J Immunol 2010;10:10.
96. Duan Z, Bradner J, Greenberg E, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1] oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 2007;72:1137-1145. (Pubitemid 350012588)
97. Jarnicki AG, Conroy H, Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efcacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797-3806.
98. Adler HS, Kubsch S, Graulich E, et al. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood 2007;109:4351-4359. (Pubitemid 46743403)
99. Barber A, Zhang T, DeMars LR, et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003-5008. (Pubitemid 46910210)
100. Bondurant KL, Crew MD, Santin AD, et al. Defnition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 2005;11:3446-3454. (Pubitemid 40627899)
101. Cannon MJ, O'Brien TJ, Underwood LJ, et al. Novel target antigens for dendritic cell-based im-munotherapy against ovarian cancer. Expert Rev Anticancer Ter 2002;2:97-105. (Pubitemid 34679462)
102. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DCmaturation and T1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107-115.
103. Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8:451-454, 2007. (Pubitemid 46621775)
104. Jin P, Han TH, Ren J, et al. Molecular signatures of maturing dendritic cells: Implications for testing the quality of dendritic cell therapies. J Transl Med 2010;8:4.
105. Roby KF, Niu F, Rajewski RA, et al. Syngeneic mouse model of epithelial ovarian cancer: Efects of nanoparticulate paclitaxel, Nanotax. Adv Exp Med Biol 2008;622:169-181.
106. Tomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 2007;121:467-473. (Pubitemid 46986477)
107. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010;363:479-481.